NeoGenomics, Inc.
NeoGenomics operates cancer-focused testing labs in US and UK. It offers various testing services to hospitals, academic centers, pathologists, and pharmaceutical companies. Services include cytogenetics, FISH, flow cytometry, immunohistochemistry, digital imaging, molecular testing, and morphologic analysis. The company also supports pharmaceutical clients oncology programs. Founded in 2001 and headquartered in Fort Myers, Florida.
Overview
Strengths
- Price to book ratio (2.34) is lower than the sector mean (9.96).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Current Price to Earnings Ratio (100.00) is significantly higher than the sector mean (67.88).
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (0.42%) is significantly lower than the sector mean (7.40%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (36.02).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data